contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …

which suggests that the elasticity of innovation with respect to the expected price of drugs should be at least as great as … the elasticity of innovation with respect to expected market size (disease incidence). Then, the cross …-sectional relationship between pharmaceutical innovation and market size among a set of diseases (different types of cancer) exhibiting …

Assessing the benefits of medical innovation—its impact on health outcomes—is as important as assessing the costs … that investigates the benefits and costs of another broad category of medical innovation—inpatient therapeutic procedure … innovation—using data on over one million hospital discharges. …

We investigate the impact of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey …

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … death) and medical expenditure in France during the period 2000–2009. The estimates imply that pharmaceutical innovation …

chemotherapy innovation on the longevity of myeloma patients using both time-series US data and longitudinal data on 38 countries. …